NCT00219765View on ClinicalTrials.gov

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2001

Study Completion Date

January 31, 2006

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Imatinib mesylate 600 mg

DRUG

Cytarabine

DRUG

Daunorubicine

Trial Locations (1)

86021

University Hospital, Poitiers

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

Novartis

INDUSTRY

lead

Poitiers University Hospital

OTHER